JP2015524403A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524403A5
JP2015524403A5 JP2015522106A JP2015522106A JP2015524403A5 JP 2015524403 A5 JP2015524403 A5 JP 2015524403A5 JP 2015522106 A JP2015522106 A JP 2015522106A JP 2015522106 A JP2015522106 A JP 2015522106A JP 2015524403 A5 JP2015524403 A5 JP 2015524403A5
Authority
JP
Japan
Prior art keywords
seq
fusion protein
domain
functional fragment
extracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015522106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524403A (ja
JP6317739B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/065248 external-priority patent/WO2014013037A1/en
Publication of JP2015524403A publication Critical patent/JP2015524403A/ja
Publication of JP2015524403A5 publication Critical patent/JP2015524403A5/ja
Application granted granted Critical
Publication of JP6317739B2 publication Critical patent/JP6317739B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015522106A 2012-07-18 2013-07-18 短縮されたCD95−Fc変異体 Expired - Fee Related JP6317739B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12176978.0 2012-07-18
EP12176978 2012-07-18
EP12176980 2012-07-18
EP12176980.6 2012-07-18
PCT/EP2013/065248 WO2014013037A1 (en) 2012-07-18 2013-07-18 Shortened cd95-fc variants

Publications (3)

Publication Number Publication Date
JP2015524403A JP2015524403A (ja) 2015-08-24
JP2015524403A5 true JP2015524403A5 (https=) 2016-08-12
JP6317739B2 JP6317739B2 (ja) 2018-04-25

Family

ID=48794121

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015522106A Expired - Fee Related JP6317739B2 (ja) 2012-07-18 2013-07-18 短縮されたCD95−Fc変異体
JP2015522107A Active JP6231562B2 (ja) 2012-07-18 2013-07-18 CD95−Fcアイソフォームの混合物を含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015522107A Active JP6231562B2 (ja) 2012-07-18 2013-07-18 CD95−Fcアイソフォームの混合物を含む組成物

Country Status (18)

Country Link
US (5) US9434783B2 (https=)
EP (4) EP3409686B1 (https=)
JP (2) JP6317739B2 (https=)
KR (1) KR102201694B1 (https=)
CN (3) CN109897115A (https=)
AU (2) AU2013291984B2 (https=)
BR (1) BR112015000732B1 (https=)
CA (2) CA2877989C (https=)
DK (2) DK2875045T3 (https=)
ES (2) ES2924109T3 (https=)
HK (1) HK1207095A1 (https=)
IL (1) IL236659A (https=)
MX (1) MX371430B (https=)
NZ (1) NZ703546A (https=)
RU (2) RU2648146C2 (https=)
SG (1) SG11201500134QA (https=)
UA (1) UA116889C2 (https=)
WO (2) WO2014013039A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3409686B1 (en) * 2012-07-18 2022-04-13 Apogenix AG Composition comprising a mixture of cd95-fc isoforms
CN105393121B (zh) * 2013-04-29 2018-04-24 阿珀吉尼科斯股份公司 诊断癌症的方法
NO2776305T3 (https=) * 2014-04-23 2018-01-27
EP3137909B1 (en) 2014-04-29 2018-06-06 Apogenix AG Diagnostic anti-cd95l antibody
US9587215B2 (en) 2014-08-07 2017-03-07 General Electric Company Devices, systems and methods for automated transfer of a sample
EP3236772A4 (en) * 2014-12-22 2018-10-17 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
US20220177841A1 (en) 2019-03-29 2022-06-09 Myst Therapeutics Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
US20230032934A1 (en) 2019-11-27 2023-02-02 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
CN114829371A (zh) * 2019-12-12 2022-07-29 Emd密理博公司 使用透析过滤缓冲液强化的病毒过滤
EP4512828A3 (en) 2020-02-27 2025-05-14 Turnstone Biologics Corp. Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
LT3972987T (lt) * 2020-04-10 2023-09-25 Akston Biosciences Corporation Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai
CN115894706A (zh) * 2021-09-30 2023-04-04 北京康辰药业股份有限公司 靶向PD-L1和FasL的融合蛋白、核苷酸序列及其应用
WO2026044087A1 (en) 2024-08-21 2026-02-26 Shape Therapeutics Inc. Increased cellular stability for aav production
WO2026073032A1 (en) 2024-09-27 2026-04-02 Shape Therapeutics Inc. Constructs for improved aav production

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306395B1 (en) 1996-05-02 2001-10-23 Mochida Pharmaceutical Co., Ltd. Fas antigen derivatives
CA2270423C (en) * 1996-10-31 2009-09-15 Mochida Pharmaceutical Co., Ltd. Prophylactic/therapeutic agent
DE69839582D1 (de) * 1997-02-27 2008-07-17 Ono Pharmaceutical Co Neues polypeptid, dafür kodierende dna und deren verwendungen
CA2309598A1 (en) * 1997-11-10 1999-05-20 Mochida Pharmaceutical Co., Ltd. Preventives and remedies for diffuse lung disease
RU2420537C2 (ru) * 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
EP1273297A1 (en) * 2001-07-06 2003-01-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Vitamin E for the treatment of diseases in which the binding of the transcription factor NF-KB and/or AP-1 to promoter target sites has a beneficial effect (eg AIDS, cardiac infarction)
PT1606318E (pt) * 2003-03-26 2009-11-10 Deutsches Krebsforsch Proteínas de fusão de fc melhoradas
US20100215637A1 (en) * 2006-03-28 2010-08-26 Biopharmica Ltd Agent for the Treatment of Hormone-Dependent Disorders and Uses Thereof
WO2007147600A2 (en) * 2006-06-21 2007-12-27 Apogenix Gmbh Differential il-4 and/or il-10 cytokine expression in human cancer
SI2428252T1 (sl) * 2006-12-28 2015-01-30 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Nevtralizacija invazije aktivnostnih blokov cd95 v celicah glioblastoma in vivo
WO2008101671A2 (en) * 2007-02-19 2008-08-28 Apogenix Gmbh Il-4 fc fusion proteins
EP2009022A1 (en) * 2007-06-26 2008-12-31 Apogenix GmbH Trimeric death ligands with enhanced activity (tenascin)
WO2010003766A2 (en) 2008-06-17 2010-01-14 Apogenix Gmbh Multimeric tnf receptors
US8664366B2 (en) * 2009-01-09 2014-03-04 Apogenix Gmbh Fusion proteins forming trimers
CN102497886B (zh) * 2009-07-21 2016-01-20 玛丽皇后与斯特菲尔德学院 用于细胞内药物递送的Fas(Apo-1,CD95)靶向平台
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ, インコーポレイテッド Fc融合タンパク質の血清半減期を増加させるための組成物および方法
EP3409686B1 (en) * 2012-07-18 2022-04-13 Apogenix AG Composition comprising a mixture of cd95-fc isoforms
CN105393121B (zh) * 2013-04-29 2018-04-24 阿珀吉尼科斯股份公司 诊断癌症的方法

Similar Documents

Publication Publication Date Title
JP2015524403A5 (https=)
JP2015525217A5 (https=)
JP2015212284A5 (https=)
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
PE20191033A1 (es) PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
EA201291362A1 (ru) Слитый белок против злокачественных новообразований
JP2012082206A5 (https=)
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
MX358725B (es) Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden.
WO2011123813A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
EA033386B1 (ru) Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение
EP3372617A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
BRPI1010880A2 (pt) polipeptídeos de hormônio de crescimento e métodos de fazer e usar os mesmos.
PE20190845A1 (es) Metodos para determinar resistencia a terapia de receptor de androgeno
PH12012502272A1 (en) Biological materials related to her3
WO2013151670A3 (en) Modified polynucleotides for the production of nuclear proteins
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
JP2013527765A5 (https=)
FI4176894T3 (fi) Kimeerisiä tekijä viii -proteiineja ja niiden käyttötarkoituksia
JP2015504052A5 (https=)
EA201491277A1 (ru) Противораковый слитый белок
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
PH12015500461A1 (en) Novel il-17a binding molecules and medical uses thereof
EP2589658A4 (en) PARTIAL REGION POLYPEPTIDE OF REIC / DKK-3 PROTEIN
RU2016145061A (ru) Профилактическая вакцина против синдрома падения яйценоскости (eds)